Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Puntos clave

• In this study, treatment dynamics were assessed with ipilimumab and nivolumab for advanced urothelial cancer, highlighting regimen effectiveness.
• The analysis involved two patient cohorts, revealing distinct outcomes based on ipilimumab dosing adjustments between high and low.
• Tumor tissues were collected pre-treatment through various methods, ensuring thorough biomarker analysis for tailored therapies.
• Findings suggest personalized treatment strategies could enhance patient outcomes in urothelial cancer management.

Resumen